Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Circulating Tumor Cells: What Is in It for the Patient? A Vision towards the Future.

van de Stolpe A, den Toonder JM.

Cancers (Basel). 2014 May 28;6(2):1195-207. doi: 10.3390/cancers6021195.

2.

Nanostructure embedded microchips for detection, isolation, and characterization of circulating tumor cells.

Lin M, Chen JF, Lu YT, Zhang Y, Song J, Hou S, Ke Z, Tseng HR.

Acc Chem Res. 2014 Oct 21;47(10):2941-50. doi: 10.1021/ar5001617. Epub 2014 Aug 11. Review.

3.

Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip.

Sheng W, Ogunwobi OO, Chen T, Zhang J, George TJ, Liu C, Fan ZH.

Lab Chip. 2014 Jan 7;14(1):89-98. doi: 10.1039/c3lc51017d. Epub 2013 Nov 13.

4.

mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.

Mostert B, Sieuwerts AM, Bolt-de Vries J, Kraan J, Lalmahomed Z, van Galen A, van der Spoel P, de Weerd V, Ramírez-Moreno R, Smid M, Verhoef C, IJzermans JN, Gratama JW, Sleijfer S, Foekens JA, Martens JW.

Mol Oncol. 2015 Apr;9(4):920-32. doi: 10.1016/j.molonc.2015.01.001. Epub 2015 Jan 21.

5.

Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges.

Lianidou ES, Markou A.

Clin Chem. 2011 Sep;57(9):1242-55. doi: 10.1373/clinchem.2011.165068. Epub 2011 Jul 22. Review.

6.

Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.

Das A, Kunkel M, Joudeh J, Dicker DT, Scicchitano A, Allen JE, Sarwani N, Yang Z, Kaifi J, Zhu J, Liao J, El-Deiry WS.

Cancer Biol Ther. 2015;16(5):709-13. doi: 10.1080/15384047.2015.1030555.

7.

Circulating tumor cells: clinically relevant molecular access based on a novel CTC flow cell.

Winer-Jones JP, Vahidi B, Arquilevich N, Fang C, Ferguson S, Harkins D, Hill C, Klem E, Pagano PC, Peasley C, Romero J, Shartle R, Vasko RC, Strauss WM, Dempsey PW.

PLoS One. 2014 Jan 29;9(1):e86717. doi: 10.1371/journal.pone.0086717. eCollection 2014.

8.

Challenges and opportunities in the use of CTCs for companion diagnostic development.

Punnoose EA, Lackner MR.

Recent Results Cancer Res. 2012;195:241-53. doi: 10.1007/978-3-642-28160-0_22. Review.

PMID:
22527511
9.

Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients.

Fischer JC, Niederacher D, Topp SA, Honisch E, Schumacher S, Schmitz N, Zacarias Föhrding L, Vay C, Hoffmann I, Kasprowicz NS, Hepp PG, Mohrmann S, Nitz U, Stresemann A, Krahn T, Henze T, Griebsch E, Raba K, Rox JM, Wenzel F, Sproll C, Janni W, Fehm T, Klein CA, Knoefel WT, Stoecklein NH.

Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16580-5. doi: 10.1073/pnas.1313594110. Epub 2013 Sep 24.

10.

Circulating cancer stem cells: the importance to select.

Yang MH, Imrali A, Heeschen C.

Chin J Cancer Res. 2015 Oct;27(5):437-49. doi: 10.3978/j.issn.1000-9604.2015.04.08. Review.

11.

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.

Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR.

Clin Cancer Res. 2012 Apr 15;18(8):2391-401. doi: 10.1158/1078-0432.CCR-11-3148. Epub 2012 Apr 5.

12.

Circulating tumor cells: the substrate of personalized medicine?

Greene BT, Hughes AD, King MR.

Front Oncol. 2012 Jul 2;2:69. doi: 10.3389/fonc.2012.00069. eCollection 2012.

13.

Circulating tumor cell isolation and diagnostics: toward routine clinical use.

van de Stolpe A, Pantel K, Sleijfer S, Terstappen LW, den Toonder JM.

Cancer Res. 2011 Sep 15;71(18):5955-60. doi: 10.1158/0008-5472.CAN-11-1254. Epub 2011 Sep 6.

14.

Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.

Kolostova K, Broul M, Schraml J, Cegan M, Matkowski R, Fiutowski M, Bobek V.

Anticancer Res. 2014 Jul;34(7):3641-6.

PMID:
24982381
15.

Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.

Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M.

Breast Cancer Res Treat. 2015 Dec;154(3):563-71. doi: 10.1007/s10549-015-3636-4. Epub 2015 Nov 16.

PMID:
26573830
16.

Isolation of rare circulating tumour cells in cancer patients by microchip technology.

Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M.

Nature. 2007 Dec 20;450(7173):1235-9.

17.

NanoVelcro Chip for CTC enumeration in prostate cancer patients.

Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM.

Methods. 2013 Dec 1;64(2):144-52. doi: 10.1016/j.ymeth.2013.06.019. Epub 2013 Jun 29.

18.

Detecting circulating tumor cells: current challenges and new trends.

Hong B, Zu Y.

Theranostics. 2013 Apr 23;3(6):377-94. doi: 10.7150/thno.5195. Print 2013. Review.

19.

Looking back, to the future of circulating tumor cells.

Friedlander TW, Premasekharan G, Paris PL.

Pharmacol Ther. 2014 Jun;142(3):271-80. doi: 10.1016/j.pharmthera.2013.12.011. Epub 2013 Dec 19. Review.

PMID:
24362084
20.

Fluorescence virus-guided capturing system of human colorectal circulating tumour cells for non-invasive companion diagnostics.

Shigeyasu K, Tazawa H, Hashimoto Y, Mori Y, Nishizaki M, Kishimoto H, Nagasaka T, Kuroda S, Urata Y, Goel A, Kagawa S, Fujiwara T.

Gut. 2015 Apr;64(4):627-35. doi: 10.1136/gutjnl-2014-306957. Epub 2014 May 28.

Supplemental Content

Support Center